Apotex’s Infringement of AstraZeneca’s Omeprazole Formulation Patent Upheld -
As previously reported, the Federal Court of Appeal, in a unanimous decision released on January 12, 2017 (2017 FCA 9), has affirmed the...more
2/4/2017
/ Apotex ,
Appeals ,
Canada ,
Canadian Institute for Health Information (CIHI) ,
Canadian Intellectual Property Office (CIPO) ,
CETA ,
Competition Authorities ,
Damages ,
Double Patent ,
Drug Pricing ,
Federal Trade Commission (FTC) ,
Health Care Providers ,
Hearsay ,
Jurisdiction ,
Medical Devices ,
Mergers ,
Motions to Quash ,
Noninfringement ,
Notice of Compliance ,
Obviousness ,
Patent Applications ,
Patent Invalidity ,
Patented Medicine Prices Review Board (PMPRB) ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
PMNOC Regulations ,
Prescription Drugs ,
Supreme Court of Canada
Janssen seeks leave to appeal to SCC regarding FCA decision upholding Minister of Health’s decisions relating to administrative drug submissions -
As reported previously, on October 12, 2016, the Federal Court of Appeal...more
12/21/2016
/ Apotex ,
Biologics ,
Burden of Proof ,
CADTH ,
Canada ,
Diagnostic Tests ,
Evidence ,
Filing Deadlines ,
Health Canada ,
Health Information Technologies ,
Hospira ,
Janssen Pharmaceuticals ,
Leave to Appeal ,
Motion for Leave ,
Motion To Strike ,
New Guidance ,
Patent Infringement ,
Patents ,
Pfizer ,
Pharmaceutical Patents ,
PMNOC Regulations ,
Prescription Drugs ,
Public Comment ,
Supreme Court of Canada ,
Teva Pharmaceuticals ,
Trademark Infringement ,
Trademarks ,
Trans-Pacific Partnership ,
Unjust Enrichment
Federal Court of Appeal opines on the framework for analyzing obviousness-type double-patenting -
On November 4, 2016, the Federal Court of Appeal dismissed Apotex’s appeal in Apotex Inc v Eli Lilly Canada Inc, 2016 FCA...more
11/30/2016
/ Accounting ,
Amgen ,
Apotex ,
Appeals ,
AstraZeneca ,
Biosimilars ,
Breach of Contract ,
Canada ,
CETA ,
Covenant of Good Faith and Fair Dealing ,
Damages ,
Double Patent ,
Drug Pricing ,
Eli Lilly ,
Free Trade Agreements ,
GlaxoSmithKline ,
Health Canada ,
Intellectual Property Protection ,
Mootness ,
Motion To Strike ,
New Legislation ,
Obviousness ,
Patented Medicines ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Pleadings ,
Prescription Drugs ,
Reversal ,
Supreme Court of Canada ,
Utility Patents